Adial Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment or prevention of addiction and related disorders. The company's lead product is AD04, a serotonin-3 antagonist, which is in Phase 3 clinical trials for the treatment of alcohol use disorder. It is also involved in the development of drug candidates for non-opioid pain reduction and other diseases and disorders. Adial Pharmaceuticals, Inc. was founded in 2010 and is based in Glen Allen, Virginia. Show more

Location: 4870 Sadler Road, Glen Allen, VA, 23060, United States | Website: https://www.adial.com | Industry: Biotechnology | Sector: Healthcare


Market Cap

6.074M

52 Wk Range

$0.22 - $3.00

Previous Close

$0.41

Open

$0.39

Volume

1,834,758

Day Range

$0.37 - $0.40

Enterprise Value

21.81K

Cash

2.366M

Avg Qtr Burn

-1.72M

Insider Ownership

3.41%

Institutional Own.

3.64%

Qtr Updated

03/31/25